Physician profile
Aravind Gopal
NPI 1386959302
$5,189.14
in general payments reported to CMS, 2019-2025
27 companies · $2,731 in 2025
The $2,731 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $110 · 2021: $193 · 2022: $451 · 2023: $764 · 2024: $340 · 2025: $2,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,737 · Education: $99.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,736.60 |
| Education | $99.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $971.84 | 2019-2025 | Evenity, Krystexxa, Otezla |
| Abbvie INC. | $833.94 | 2019-2025 | |
| Pfizer INC. | $688.29 | 2019-2025 | |
| Ucb, INC. | $457.40 | 2023-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $420.47 | 2019-2025 | Tremfya |
| Radius Health, INC. | $232.60 | 2025 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $179.45 | 2025 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $179.35 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $178.42 | 2019-2021 | |
| Genzyme Corporation | $138.04 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $127.83 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $126.31 | 2022-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $118.96 | 2019-2020 | |
| Horizon Therapeutics Plc | $104.41 | 2019-2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $83.63 | 2023-2025 | Tyenne |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $58.94 | 2019 | |
| Ani Pharmaceuticals, INC. | $45.10 | 2025 | Purified Cortrophin Gel |
| Incyte Corporation | $37.02 | 2022-2023 | Jakafi |
| Alexion Pharmaceuticals, INC. | $33.81 | 2025 | Strensiq |
| Seagen INC. | $33.66 | 2022 | |
| Lilly USA, LLC | $27.88 | 2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.03 | 2021 | |
| Sobi, INC | $25.09 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.89 | 2020 | |
| Ironwood Pharmaceuticals, INC | $15.85 | 2019 | |
| Kyowa Kirin, INC. | $13.71 | 2025 | |
| Ferring Pharmaceuticals INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aravind Gopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.